title: Omalizumab is effective in nonautoimmune urticaria.
authors.forename: Marta
authors.initials: M
authors.lastname: Ferrer
authors.forename: Pedro
authors.initials: P
authors.lastname: Gamboa
authors.forename: Maria L
authors.initials: ML
authors.lastname: Sanz
authors.forename: Maria Jose
authors.initials: MJ
authors.lastname: Goikoetxea
authors.forename: Paula
authors.initials: P
authors.lastname: Cabrera-Freitag
authors.forename: Gracia
authors.initials: G
authors.lastname: Javaloyes
authors.forename: Felicia
authors.initials: F
authors.lastname: Berroa
authors.forename: Allen P
authors.initials: AP
authors.lastname: Kaplan
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000503:physiopathology; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab